<?xml version="1.0" encoding="UTF-8"?>
<p id="Par33">Combined use of famitinib and CCRT (cisplatin, 80 mg/m
 <sup>2</sup>) is well tolerated at 20 mg/day or lower in patients with NPC. The results also suggest that D-CEUS could be used to evaluate tumour vascularization and efficacy in patients with NPC treated with famitinib.
</p>
